Machine learning for high-content analysis: User stories
Scientists from the University of Washington are using the Phenoglyphs machine learning module to achieve faster high-content analysis through automation and simplification.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Breakthrough in liquid biopsy
/in News/by Thomas GabrielczykGerman and US researchers have developed a diagnostic technique capable to detect one single circulating tumour cell in one litre of blood.
ADC Therapeutics raise $76m in Series E expansion
/in News/by Thomas GabrielczykSwiss antibody drug conjugate developer ADC Therapeutics SA raised $76m, bringing the total gross proceeds to $276 million in its Series E financing.
Evotec bags US$23.8m to fight tuberculosis
/in News/by Thomas GabrielczykThe Bill & Melinda Gates Foundation has granted Evotec SE $23.8m to identify the best drug combos to fight tuberculosis.
How lungs trigger innate lymphoid cell dynamics
/in News/by Thomas GabrielczykThe cells surrounding structures play an important role as cues from the immune system in guiding their motility and behaviour, researchers from the UK and the US report.
Researchers find clue to Parkinson’s gene therapy
/in News/by Thomas GabrielczykAn enzyme that clears out alpha-synuclein from neurons may counteract Parkinsons Disease, report researchers from ETH Zürich and Novartis.
Chikungunya vaccine developer Themis bags $21m
/in News/by Thomas GabrielczykUnder a partnering ageement with CEPI, Themis Bioscience will receive $21m to push pivotal testing of MV-CHIK, its Chikungunya vaccine candidate.
Genetically modified fungus stops malaria mosquitoes
/in News/by Thomas GabrielczykA fungus that produces an insecticide can stop the spread of Anopheles mosquito, which causes malaria.
Abacus Medicine postpones IPO
/in News/by Thomas GabrielczykEuropean pharmaceutical parallel trade company Abacus Medicine A/S has postponed its planned Initial Public Offering (IPO), due to "unfavourable market environment".
Make leukaemia therapy safer
/in News/by Thomas GabrielczykA Belgian-British-Australian research team has created a safer version of a therapy that combats the aggressive form of a blood cancer called acute lymphoblastic leukemia (ALL) while avoiding toxicity.